The BARD score was developed in a retrospective study involving 827 patients with biopsy-proven NAFLD and is an easily calculated index score which is derived by the sum of three parameters, namely BMI > 28 kg/m2 (1 point), AST/ALT ratio > 0.8 (2 points) and diabetes (1 point) [89]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.